8 NMSS Board members with drug company links

[Guest guest]

At least eight of the directors of the NMSS have some degree of

connection to the pharmaceutical industry. They along with their

links and documentation of the links are listed below.

The most significant are the first two. The first is the lone

medical voice on the NMSS board. He is in charge of a department

which conducts trials for MS drugs (= steroids) for the drug

industry. The second is the chairman. His company does a lot of

work for the pharamceutical companies. If he is sympathetic to Dr.

Lubin, and if the other members of the board with lesser links to the

industry are at all sympathetic to these two, it will be essentially

impossible for any other voice to be heard on the board.

Also, please remember that in my post 14152 I explained that these

are all external links, they are not records of conversations nor of

voting. All that this information does is disclose a tight

relationship between the drug companies and the NMSS. Every board

member can vote his conscience and LDNers may have some friends on

the board even among those on this list. However, when one sees

the irrational hostility of the NMSS to LDN and similar treatments,

the list provides a pathway that drug companies might be able to use

to influence the NMSS board.

1.

Fred D. Lublin, MD

Director

Corinne Goldsmith Dickinson

Center for Multiple Sclerosis

Department of Neurology

Mount Sinai School of Medicine

Mount Sinai School of Medicine bills itself not only as a school of

medicine, but as one of the leading medicial research institutions in

the country.

http://www.mssm.edu/research/clinical_research.shtml is a web page

showing their current research. On this page, click on clinical

trials. Mt. Sinai is lists 38 clinical trials it is doing for the

drug companies. On the page, at the pull down list for Diseases and

Conditions, find Multiple Sclerosis and click on it, then on the

search button.

There are currently two projects being funded by the drug companies

at Mt. Sinai, one for copaxone in 40 mg capsules and another for

megadoses of steroids for acute exacerbations in RRMS.

Dr. Lublin is the director of the center doing these studies. He

will certainly have the ear of the board of NMSS concerning the

medical input to the society.

So, the only doctor on the NMSS board is in charge of a medical

school reserach department that does the MS clinical research for the

drug companies and which is now actively researching MEGADOSES of

steroids.

If you do not believe in steroids, and have been hoping that NMSS

might provide the research for an alternative, this is scary.

***********************

2.

Chairman of the Board, NMSS

A. Kangas

Deloitte Touche Tohmatsu

The webpage for Deloitte is at http://www.deloitte.com/dtt/home/

Links can be followed from this page to " Industries " and then " Life

Science and Health Care " .

The first sentence of this page reads " Large biopharmaceutical

companies are facing unprecedented challenges to further growth .... "

Mr. Kangas is the chairman and retired CEO of Deloitte.

So, the chairman of the NMSS is also the chairman of a huge firm (per

other references from their website) which services the

pharmaceutical industry amongst others.

The chairman controls the tenor and progress of a meeting. If Mr.

Kangas is sympathetic to the expected position of

*************************

3.

G. Tarricone

CEO

Herder Tarricone Associates

http://www.htwa.com/aboutus.html

Business Services " Insurance "

" a strong client base in the electronics, manufacturing, medical

products, ... "

***********************

4.

Milt

Tremaine LLP

http://www.dwt.com/

http://www.dwt.com/practc/healthcr/legalservices.cfm

Whether you are providing health care, developing information

technology and bio-informatics, or researching new medical drugs or

devices, you are subject to complex regulatory risks. Few industries

undergo continual transformation with such high stakes. Responding to

these challenges with depth of experience and personalized service

has earned Tremaine its reputation as a leading national

health law practice.

**************************

5.

Eli stein

Partner

Goulston & Storrs

counselors at law

http://www.goulstonstorrs.com/

path: " service area " to " technology " to " Life sciences and

medical devices " . Page gives a list of clients. A number of

pharmaceutical companies are listed.

***************************

6.

Craig T. Lynch

Partner

, Poe, &

Bernstein LLP

http://www.parkerpoe.com/practice/biotechnology.cfm

Lists the activities among his firm as including writing contracts

for clinical trials.

*************************

7. Jenckes

Jenckes & Associates

Washington, DC

Ms. Jenckes is also a director of NABI Biopharmaceuticals:

http://www.nabi.com/who_leadership.html

**********************

8. A. Bogdonoff, Esq.

Discussed in post 1411